Tracers / [211At]At-NaAt
[211At]At-NaAt
Also written as [At-211]NaAt
- Radionuclide
- At-211 t½ 431 min
- Modality
- Therapy
- Production route
- —
- Stage
- investigational product for investigator-initiated clinical trial
- Syntheses indexed
- 2
What it is
- Compound class
- Sodium astatide (inorganic astatide salt, NaAt)
- Target / mechanism
- —
- Clinical application
- Targeted alpha therapy for refractory thyroid cancer resistant to conventional radioiodine therapy PMID 38619655
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| COSMiC-Mini NMP Business Support | custom manifold | none | 40 ± 3% yes | 97 ± 1% | — | 38619655 2024 EJNMMI Radiopharm Chem the automated dry distillation system COSMiC-Mini VTRSC2 (Nihon Mediphysics Business Support, Hyogo, Japan) — radiochemical yield of [211At]NaAt were 78.8 ± 6.0 MBq and 40 ± 3%, respectively |
| — | — | — | — | — | — | 41765488 2026 Yakugaku Zasshi |
Need this precursor?We can point you to suppliers for [211At]At-NaAt, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 38619655: 'to conduct an investigator-initiated clinical trial'.